

## HR 1344

Competitive DRUGS Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 25, 2019

**Current Status:** Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

**Latest Action:** Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. (Mar 25, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/1344>

### Sponsor

**Name:** Rep. Doggett, Lloyd [D-TX-35]

**Party:** Democratic • **State:** TX • **Chamber:** House

### Cosponsors (21 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Feb 25, 2019
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Feb 25, 2019
Rep. Cartwright, Matt [D-PA-8]	D · PA		Feb 25, 2019
Rep. Chu, Judy [D-CA-27]	D · CA		Feb 25, 2019
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Feb 25, 2019
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Feb 25, 2019
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Feb 25, 2019
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Feb 25, 2019
Rep. Hill, Katie [D-CA-25]	D · CA		Feb 25, 2019
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Feb 25, 2019
Rep. Khanna, Ro [D-CA-17]	D · CA		Feb 25, 2019
Rep. Langevin, James R. [D-RI-2]	D · RI		Feb 25, 2019
Rep. Moore, Gwen [D-WI-4]	D · WI		Feb 25, 2019
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Feb 25, 2019
Rep. Ocasio-Cortez, Alexandria [D-NY-14]	D · NY		Feb 25, 2019
Rep. Pingree, Chellie [D-ME-1]	D · ME		Feb 25, 2019
Rep. Pocan, Mark [D-WI-2]	D · WI		Feb 25, 2019
Rep. Waters, Maxine [D-CA-43]	D · CA		Feb 25, 2019
Rep. Welch, Peter [D-VT-At Large]	D · VT		Feb 25, 2019
Rep. Garamendi, John [D-CA-3]	D · CA		Feb 26, 2019
Rep. Porter, Katie [D-CA-45]	D · CA		Feb 26, 2019

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 26, 2019
Judiciary Committee	House	Referred to	Mar 25, 2019
Ways and Means Committee	House	Referred to	Feb 25, 2019

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
116 HR 2375	Related bill	<b>Dec 24, 2020:</b> Placed on the Union Calendar, Calendar No. 576.
116 S 64	Related bill	<b>Jan 9, 2019:</b> Read twice and referred to the Committee on the Judiciary.

## Summary (as of Feb 25, 2019)

### Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 or the Competitive DRUGS Act of 2019

This bill authorizes the Federal Trade Commission to initiate a proceeding against parties to an agreement resolving or settling a patent infringement claim in connection with the sale of a drug. Such an agreement is generally presumed to be an unfair method of competition and is a violation of this bill if the filer of the generic drug application receives something of value and agrees to limit or forgo research, development, manufacturing, marketing, or sales of the generic drug.

However, an agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market the generic drug prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on a claim that the generic drug infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh its anticompetitive effects.

The bill establishes penalties for violations of the bill.

## Actions Timeline

- **Mar 25, 2019:** Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- **Feb 26, 2019:** Referred to the Subcommittee on Health.
- **Feb 25, 2019:** Introduced in House
- **Feb 25, 2019:** Referred to the Subcommittee on Health.
- **Feb 25, 2019:** Referred to the Committee on Ways and Means, and in addition to the Committees on Energy and Commerce, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.